tbuckley/cabot-search huggingface dataset:
クリック化学は筋肉に触発されたクエン酸抗微生物バイオ接着剤の湿潤接着強度を改善した【Powered by NICT】
Authors: Guo Jinshan, B Kim Gloria, Shan Dingying, P Kim Jimin, Hu Jianqing, Wang Wei, G Hamad Fawzi, Qian Guoying, B Rizk Elias, Yang Jian
Journal: Biomaterials (2017)
AB0958 Proposal for a juvenile systemic sclerosis response index (JSSCRI): result of the consensus meeting in hamburg. germany 11th of december 2016
Authors: I Foeldvari, DF Furst, J Anton, E Baildem, M Blakley, T Constantin, P Costa Reis, M Curran, M Cutolo, C Denton, K Fligelstone, B Hinrichs, F Ingegnoli, A Kienast, D Němcova, C Pain, C Pilkington, V Smith, D Khanna
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Juvenile Systemic Sclerosis (jSSc) is an orphan disease. There is increasing interest in testing novel therapies in the management of fibrotic diseases. Therefore, it is very important to develop a Response Index for jSSc (JSScRI) to distinguish effective therapies from placebo. In 2014 at the 1st JSScRI Consensus Meeting in Hamburg, following two rounds of a Delphi process, a proposal for domains and items for a JSScRI were made. In 2016, the 2nd JSScRI Consensus Meeting was held in Hamburg, Germany. <h3>Objectives</h3> To conduct a Nominal Group Technique (NGT) and select potential core data set items that could change as outcome measures) that will be incorporated in the development of a JSScRI. <h3>Methods</h3> Before the 2nd JSScRI Consensus Meeting, the items from the 1st JSScRI Consensus Meeting (2014) were scored via Email, in a Delphi by the participants of the current meeting. Participants included 14 experts in adult and juvenile SSc and a patient partner. During the subsequent face to face NGT meeting, moderated by DEF, and the items were scored anonymously by the participants after a nominal group discussion. The domains and items were scored regarding their importance for 1 year clinical trial from 1 (not relevant at all) to 9 (most relevant). A priori, it was agreed by the participants that the goal of the NGT was to exclude items that: 1. Are not feasible and 2. do not represent a changeable outcome measure even though they may represent the impact of disease on quality of life, vocational or recreational activity. Items with a median score of &lt;4 in which greater than 1/3 of participants scored 1–3 [despite the item having a median score &gt;3] were excluded. <h3>Results</h3> Seventy-one items in 13 domains were scored. Six items were not scored as they were felt to not represent an outcome measure or were non-feasible and six items received a median score less then 4. Table 1 provides an example of the musculoskeletal domain with the median scores for different outcome measures. <h3>Conclusions</h3> In a rigorous, NGT consensus meeting, some item reduction for the JSScRI was achieved. Items will be tested in a prospective way in the patients of the inception cohort of juvenile SSc (www.juvenile-scleroderma.com). <h3>Disclosure of Interest</h3> None declared
Soldier with brain injury can have experimental stem cell therapy, says judge
Authors: Clare Dyer
Journal: BMJ (2017)

A High Court judge has provisionally cleared the way for a soldier disabled by a traumatic brain injury to undergo experimental stem cell treatment at a clinic in Belgrade.

The application by the lance corporal’s mother was opposed by the Ministry of Defence, which is responsible for his care, and the official solicitor, who acted for him in the case at the Court of Protection.

Both argued that there was not enough evidence that the treatment was safe.

Mr Justice Baker ruled that the 27 year old soldier, referred to as D, lacked the capacity to make his own decisions about medical treatment. But D was adamant that he wanted the treatment …
FRI0455 Radiographic progression of hip arthritis in patients with ankylosing spondylitis treated with tnf inhibitors
Authors: M Konsta, MT Nurmohamed, A Iliopoulos, JC van Denderen, I Visman, PP Sfikakis, IE van der Horst-Bruinsma
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Although there is debate whether treatment with TNF inhibitors (TNFi) in AS may not inhibit spinal radiographic progression, the effect on hip involvement may be different (1,2). <h3>Objectives</h3> To estimate the impact of long-term TNFi treatment on radiographic progression of hip arthritis in AS, by adding a quantitative scoring method, previously applied in hip osteoarthritis, to the BASRI-hip score. <h3>Methods</h3> Consecutive TNFi-naïve AS patients (fulfilling the modified New York criteria) who were eligible for TNFi treatment were included. Hip involvement was assessed clinically (pain, reduced range of motion and intermalleolar distance) and radiographically. X-rays of the pelvis and lateral cervical and lumbar spine were obtained at 3 time points: at baseline two and seven years after the start of TNFi. Both hips were scored using: a) BASRI-hip score (BASRI-h score ≥2 is classified as definitive hip involvement), b) mean joint space width (MJSW), estimated by measurement of 3 distinct points of interbone distance: 2mm inner of the external end of the acetabulum, vertical line through femoral head center, head-neck center line (1). Spinal X-rays were scored were scored blindly, by 2 independent readers using the mSASSS. The significance of changes was tested by mixed models for longitudinal data. <h3>Results</h3> 262 AS patients (188 men, age: 49.8±12 years, disease duration: 24.4±12 years) under TNFi treatment were included. Definite hip involvement at baseline was detected in 95/262 (36%) patients, who had significantly higher BASRI-hip score [2 (2–2.5) median (IQR) vs. 0.5 (0–1) p&lt;0.0001] and lower MJSW (3.6±0.7 vs. 4.5±0.7, p&lt;0.0001), compared to those without. In patients with hip arthritis at baseline, both BASRI-h score and MJSW remained unchanged during follow up. In patients without hip arthritis, the BASRI-hip score remained unchanged after 2.5±0.7 years, but increased significantly after 7±2.3 years compared to baseline. In contrast, the MJSW in patients without hip arthritis remained unchanged at the three time points. The mSASSS raised significantly during the follow-up period, regardless of hip involvement (see table). <h3>Conclusions</h3> One third of the AS patients suffer from radiographic hip involvement, which seems to stabilize during long-term anti-TNF treatment. Assessment of MJSW may contribute to detect minor changes in contrast to BASRI-hip score9 rough estimation. <h3>References</h3> Konsta M, et. al, Clin Rheumatol. 2013 Aug;32(8):1229–32. Nystad TW, et. al. Annals of the rheumatic diseases. 2014 Jun;73(6):1194–7. <h3>Disclosure of Interest</h3> None declared
Two-Stage Model for Breast Carcinogenesis in Females: Reply
Authors: Suresh H. Moolgavkar
Journal: JNCI Journal of the National Cancer Institute (1981)

Two-Stage Model for Breast Carcinogenesis in Females: Reply Get access Suresh H. Moolgavkar Suresh H. Moolgavkar Institute for Cancer Research7701 Burholme Avenue Philadelphia, Pa. 19111 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 67, Issue 4, October 1981, Pages 745–746, https://doi.org/10.1093/jnci/67.4.745 Published: 01 October 1981
<i>AACR Cancer Progress Report 2017:</i> Harnessing Research Discoveries to Save Lives
Authors: Marlowe S. Tessmer, Keith T. Flaherty
Journal: Clinical Cancer Research (2017)

Clinical Cancer Research ( CCR ) is proud to announce the release of the American Association for Cancer Research (AACR) Cancer Progress Report 2017 . This seventh edition of the annual report focuses on the research that contributed to advances in cancer prevention, detection, diagnosis, and
Genome-wide association study identifies 112 new loci for body mass index in the Japanese population
Authors: Masato Akiyama, Yukinori Okada, Masahiro Kanai, Atsushi Takahashi, Yukihide Momozawa, Masashi Ikeda, Nakao Iwata, Shiro Ikegawa, Makoto Hirata, Koichi Matsuda, Motoki Iwasaki, Taiki Yamaji, Norie Sawada, Tsuyoshi Hachiya, Kozo Tanno, Atsushi Shimizu, Atsushi Hozawa, Naoko Minegishi, Shoichiro Tsugane, Masayuki Yamamoto, Michiaki Kubo, Yoichiro Kamatani
Journal: Nature Genetics (2017)
THU0313 Inferior and superior vena cava thrombosis in behcet s disease. moroccan experience
Authors: FZ Alaoui, M Moudatir
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Behcet9s disease (BD) is a systemic disorder with a vascular tropism where the vessels might be affected. Venous thrombosis is the most common vascular complication. Among its locations, vena cava thrombosis (VCT) are rare but can be life-threatening. The purpose of this work is to specify the frequency of VCT in the course of Behcet9s disease in morocco and to analyse epidemiological, clinical and therapeutic modalities. <h3>Objectives</h3> This retrospective study was conduced in the internal medicine department of the University Hospital IbnRochd of Casablanca, over a period of thirty-five years between 1980 and 2016. <h3>Methods</h3> Where included 1618 cases of Behcet9s disease, all diagnosed in our service and meeting the diagnosis criteria as defined by the international study group (ISG) for Behcet9s disease. <h3>Results</h3> 52 patients with VCT – 47 men and 4 women - were gathered during this period, representing a rate of 3.30% of 1572 cases, with a mean age of 35 years (ranges 17–54). The diagnosis of VCT and BD was concomitant in 10 cases and occurred during the course of the disease in 42 cases after an average of 6 years of evolution. Among the localization. Inferior VCT is the most frequent localization ( 32 patients, including 15 cases of Budd- Chiari syndrome). The superior VCT was reported in 24 patients, whereas 5 patients had both a superior and inferior VCT.Vena cava thrombosis was associated with deep venous thrombosis (DVT) of the lower limbs in 24 cases and with an aneurysm in 7 cases (pulmonary artery: 4 cases, femoral artery: 2 cases, abdominal aorta; 1 case). Regarding the therapeutic modalities, 41 patients were under anti-coagulant treatment, 45 patients received corticosteroids and 51 of the patients were under immunosuppressive agents (cyclophosphamide,azathioprine). The evolution was significantly improved after the introduction of the immunosuppressive therapy, which were firstly initiated in 2006. <h3>Conclusions</h3> Vena cava thrombosis in the context of Behcet9s disease is a very serious pathology threatening the patient9s vital and functional prognosis. Preventive measures, early diagnosis and effective treatment are the keys to a successful management of such complications9 risks. <h3>Disclosure of Interest</h3> None declared
OP0279-PARE NRAS know your das app self assessment tool empowering patients
Authors: CB Jacklin, S Arora
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> NRAS has worked with Roche/Chugai for many years on the Know Your DAS resources. As the DAS28 is the most utilised disease measuring tool available and is used in many countries as part of the access criteria <h3>Objectives</h3> In 2015 the charity was approached about developing an app for mobile phone and tablet use to encourage DAS patient self-assessment. As well as developing the app we worked with the pharmaceutical company to develop printed updated booklets for both patients and health professionals with the addition of information on DAS self-assessment contained within. With increasing pressures on rheumatology clinic time and the emphasis on improving patient education and empowerment this additional NRAS resource is timely and much in demand. <h3>Methods</h3> The Know Your Das app was designed with clear step by step guides and how to video clips to demonstrate how to use the app and show how patients should examine their own joints. NRAS hosted two user testing focus group meetings and after the launch of version one real time use was analysed. In Jan 2017 version two was released with improvements to the usability and additions including sections on adherence and stock management to aid with prescription refills. The information entered is held securely by the individual but the DAS results can be printed off or emailed to their clinicians as appropriate. It is not envisaged that the patients9 self-assessment should entirely replace the clinicians9 DAS measurements but that it will facilitate a better dialogue at clinic appointments as it will give a clearer picture of how the disease has been active or not in the intervening time between appointments. <h3>Results</h3> As of January 2017, 2217 people have downloaded the Know your DAS app and much interest has been shown by users from outside the UK who would like to be able to use the app. Clinicians are keen to utilise the app with their patients <h3>Conclusions</h3> Further research needs to be carried out to compare patients adherence, engagement with their clinicians and ownership of their disease managment as a direct result of using the Know Your DAS app. <h3>Acknowledgements</h3> Roche/Chugai Pharmaceuticals for their funding and development of this resource <h3>Disclosure of Interest</h3> C. Jacklin Grant/research support from: Roche/Chugai Pharmaceuticals, S. Arora: None declared
OP0245 Employment perspectives of patients with ankylosing spondylitis in the biologics era
Authors: C Webers, L Vanhoof, S van Genderen, G Plasqui, L Heuft, M van de Laar, J Luime, D van der Heijde, A Spoorenberg, A Boonen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> In the pre-biologics era, employment of patients with ankylosing spondylitis (AS) was decreased when compared to the general population. However, information on standardized employment since the introduction of biologicals is lacking. Also, while mastery (control over disease) has been identified as strong predictor of work outcome within patients with AS, it is not known whether such personality trait plays a similar role in patients compared to population subjects. <h3>Objectives</h3> To update the knowledge on employment and contributing factors, in particular personal factors, among Dutch patients with AS compared to general population subjects. <h3>Methods</h3> Data from patients and population controls participating in the Dutch cross-sectional multicenter survey-based Social Participation in AS Study (SPASS) and ≤65 years were used. Standardized employment ratios (SERs) were calculated using indirect standardization after adjusting for age, gender and education and were stratified by disease duration tertiles. Adjusted absolute employment rate (%) was calculated as "SER[AS]*employment rate [controls]". Modified Poisson regressions were performed to understand the role of mastery as a personal factor (Pearlin9s Mastery scale) in patients opposed to controls, independent of socio-demographics (age, gender, education) and health-related factors (comorbidities, Physical Component Summary (PCS) of the SF-36). <h3>Results</h3> 214 patients and 470 controls (127 [59.3%] and 323 [68.7%] males; mean age of 48.3 [SD 10.4] and 39.3 [SD 12.7] years, respectively) completed the online questionnaire in 2011. SERs (95% CI) of patients with AS with controls set as reference (1.00) were 0.83 (0.69–0.98) for the total group, 0.84 [0.67–1.04] for males and 0.83 [0.59–1.07] for females. There was no significant difference in SER between those with short or long disease duration (Figure 1). Adjusted absolute employment rate (%) of patients with AS was 14% lower compared to controls (69% vs. 84%). In both patients and controls, higher PCS (SF-36) was associated with being employed. While AS patients with higher (better) mastery were more likely to be employed, such association was not seen in controls (p&lt;0.01 for interaction group*mastery) (Table). <h3>Conclusions</h3> In the biologics era, employment among Dutch patients with AS remains reduced when compared to the general population, also in those with less than 15 years disease duration. As mastery in patients is independently associated with work outcome, it is worthwhile exploring whether improving personal self-management skills supports future worker participation. <h3>Disclosure of Interest</h3> None declared
Targeting polo-like kinase 1 and TRAIL to enhance apoptosis in non-small cell lung cancer (NSCLC) cells.
Authors: Alfiah Noor, Ijeoma Adaku Umelo, Peter Kronenberger, Erik Teugels, Jacques De Greve
Journal: Journal of Clinical Oncology (2017)

e14104 Background: TNF-related apoptosis-ligand (TRAIL) can selectively induce apoptosis in cancer cells without causing damage to normal cells. However, some tumors are resistant to TRAIL monotherapy and clinical studies assessing targeted agents towards the TRAIL receptor have failed to show robust therapeutic activity. A number of studies have reported that the combination of targeted agents against the TRAIL receptor with standard systemic therapy and another targeted therapy considerably increased anti-tumor activity in experimental NSCLC models. Polo like kinase 1 (PLK1) is an emerging anti-mitotic target for NSCLC with high selectivity. Depleting PLK1 has been shown to reduce cell proliferation and induce apoptosis in NSCLC cells but not in normal cells. Both PLK1 and TRAIL-induced apoptosis pathways are important in supporting the malignant phenotype. We postulated that inhibiting PLK1 could enhance TRAIL-induced apoptosis. We therefore combined human recombinant TRAIL (rhTRAIL) and the PLK1 inhibitor RO3280, and studied the effect of combinatorial treatment on NSCLC cells. Methods: Cell growth was assessed by MTS assay and apoptotic activity by FACS and western blot analysis. The effect of combinatorial treatment on MAPK/ERK, PI3K/Akt and JAK/STAT signaling pathways that play an essential role in the survival of NSCLC cells were investigated by western blot analysis. Results: In this study, we demonstrate that the combination of a rhTRAIL with RO3280 synergistically reduces cell growth and strongly increases apoptotic activity in NSCLC cells. In response to RO3280 treatment, STAT3 activity is inhibited, possibly contributing to the sensitization of NSCLC cells to TRAIL-induced apoptosis. Blockade of STAT3 activity with a STAT3 inhibitor (stattic) and siRNA-mediated knockdown of STAT3 significantly enhances TRAIL-induced apoptosis in NSCLC cells. Conclusions: Our results suggest that this synergistic effect might occur through the inhibition of STAT3 activity which in turn may further contribute to the sensitization of the NSCLC cells to TRAIL therapy. Taken together, our results support the further exploration of PLK1 inhibitors in combination with TRAIL therapy in the treatment of NSCLC.
THU0291 Gender influence on clinical, biological and immunological aspects of systemic lupus erythematosus
Authors: T Ben Salem, M Tougorti, I Naceur, I Ben Ghorbel, M Lamloum, MH Houman
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is more frequent in women but seems to be more severe in men. <h3>Objectives</h3> The aim was to study gender influence on clinical, biological and immunological features of SLE <h3>Methods</h3> It9s a retrospective study conducted in an internal medicine department. Patients with systemic lupus erythematosus (ACR revised criteria) were included. Data were recorded and compared using SPSS. Variables with a p≤0.05 were considered to be statistically significant. <h3>Results</h3> A total of 246 SLE patients were included; 224 female and 19 male (sex ratio F/M was 11.78). Mean ages at disease onset and at SLE diagnosis were comparable for men and women respectively 35.63±14.31 vs 32.7±13.36 years and 35.8±14.3 vs 34.5±13.6 years. SLE diagnosis was made earlier in men with an average delay (from first sign of the disease to diagnosis) of 6.1 months vs 21.4 months (p=0.02). Clinically, photosensitivity was significantly more frequent in women (81.4% vs 58.8%; p=0.03). Women complained from alopecia more frequently than men but the difference was not statistically significant (35.1% vs 14.3%; p=0.09). Arthritis were two times more frequent in women (50.7% vs 25%; p=0.04). Lupus nephritis us well us lupus pancreatitis were significantly more frequent in men, respectively 66.7% vs 41.6% (p=0.039) and 11.1% vs 1.4% (p=0.047). There were no differences according to gender in neurological involvement and seritis. No significant differences were observed between men and women concerning hematological disorders. Anti-DNA, anti-Sm, anti-RNP, anti-SSA, anti-SSB, anti-cardiolipin and anti-B2GP1 antibodies frequencies were similar in both genders. <h3>Conclusions</h3> SLE diagnosis was made earlier in men than women, this could be explained by more severe disease in men [1]. However this hypothesis has been highly controversial [2]. Cutaneous and joints manifestations seem to be more frequent in women whereas serious manifestations like lupus nephritis and neurological involvements were more frequent in men [3–4]. In our study, only lupus nephritis and pancreatitis were more frequent in men. <h3>References</h3> Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 2007;56:622–30. Murphy G, Isenberg D. Effect of gender on clinical presentation in systemic lupus erythematosus. Rheumatology (Oxford). 2013;52:2108–15. Tan TC, Fang H, Magder LS, Petri MA. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol. 2012;39:759–69. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Medicine. 2016;95(29):e4272. <h3>Disclosure of Interest</h3> None declared